# Henagliflozin in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct05252624` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05252624](<https://clinicaltrials.gov/study/NCT05252624>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05252624

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05252624. Randomized; triple masking; primary purpose prevention. Start 2022-09-01 (anticipated); primary completion 2023-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05252624, source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)
- Planned start: 2022-09-01 (anticipated) (ClinicalTrials.gov record NCT05252624, source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)
- Primary completion: 2023-09-30 (anticipated) (ClinicalTrials.gov record NCT05252624, source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)
- Completion: 2023-09-30 (anticipated) (ClinicalTrials.gov record NCT05252624, source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05252624, source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05252624-2022-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Henagliflozin in Patients With Atrial Fibrillation
- Acronym: HENA-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): placebo
- Intervention (Drug): Henagliflozin 5Mg Tab
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 4d837aac0a6dd3a63ebfb8f01278b57e1df5a739a9b240ba8af30cb6fe950ae3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
